Engineering hepatocyte-targeted LNPs for RNA and DNA delivery to primary human T cells

This presentation outlines a study that aims to develop potent lipid nanoparticles (LNPs) as an alternative to lentiviral vectors for delivering genes of interest into T cells. ElevateBio’s proprietary LNP platform enables highly efficient RNA and DNA delivery to primary human T cells, with greater than>90% efficiency. Our LNPs also outperform electroporation (EP) in delivering hard-to-deliver payloads, such as large insertion DNA constructs (>85% vs ~20%), addressing the unmet need for efficient large gene insertion delivery.